Find Paid Clinical Trials in Arizona

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Arizona

Top of Directory » All Locations » United States » Arizona




  • Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

    Condition:   Advanced Solid Tumors
    Interventions:   Drug: BIIB021 and Food;   Drug: BIIB0121 and Antacid
    Sponsor:   Biogen Idec
    Recruiting - verified November 2009

  • Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors

    Condition:   Advanced or Metastatic Solid Tumors
    Intervention:   Drug: NMS-1286937
    Sponsor:   Nerviano Medical Sciences
    Not yet recruiting - verified November 2009

  • Electronic Brachytherapy for the Treatment of NMSC

    Conditions:   Basal Cell Carcinoma;   Squamous Cell Carcinoma
    Intervention:   Radiation: electronic brachytherapy
    Sponsor:   Xoft, Inc.
    Recruiting - verified November 2009

  • ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

    Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: ABT-888;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Phase IIb 78-week Study in Patients on a Basal Insulin +/- Metformin and/or Sulfonylurea and Are Not at Goal to Add BI 10773 vs. Placebo

    Condition:   Diabetes Mellitus, Type 2
    Intervention:   Drug: BI 10773
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified November 2009

  • In Vivo Confocal Microscopy Tumor Atlas Study

    Condition:   Brain Neoplasms
    Intervention:   Device: Endomicroscope
    Sponsor:   Carl Zeiss Surgical GmbH
    Recruiting - verified November 2009

  • Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: MN-221 (Dose Group 1);   Drug: MN-221 (Dose Group 2);   Drug: MN-221 (Dose Group 3)
    Sponsor:   MediciNova
    Recruiting - verified November 2009

  • First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously And Subcutaneously To Healthy Adult Volunteers

    Condition:   Healthy Volunteers
    Interventions:   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009

  • Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

    Condition:   Thymic Carcinoma
    Intervention:   Drug: PHA-848125AC
    Sponsor:   Nerviano Medical Sciences
    Not yet recruiting - verified November 2009

  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009

  • A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Pulmonary Disease, Chronic Obstructive
    Interventions:   Drug: GW642444 Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Study Evaluating the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis

    Condition:   Active Rheumatoid Arthritis
    Intervention:   Drug: SBI-087
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

    Conditions:   Proctitis;   Proctosigmoiditis
    Interventions:   Drug: Budesonide;   Drug: Placebo
    Sponsor:   Salix Pharmaceuticals
    Not yet recruiting - verified November 2009

  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

    Condition:   Onychomycosis
    Interventions:   Drug: IDP-108;   Drug: Vehicle
    Sponsor:   Dow Pharmaceutical Sciences
    Not yet recruiting - verified November 2009

  • Study of A3309 in Patients With Chronic Idiopathic Constipation

    Conditions:   Constipation;   Chronic Constipation
    Intervention:   Drug: A3309
    Sponsor:   Albireo
    Recruiting - verified November 2009

  • ACT-128800 in Relapsing-remitting Multiple Sclerosis

    Condition:   Relapsing-Remitting Multiple Sclerosis
    Interventions:   Drug: ACT-128800;   Drug: Placebo
    Sponsor:   Actelion
    Recruiting - verified October 2009

  • Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

    Conditions:   Arthritis;   Arthritis, Rheumatoid;   Autoimmune Diseases
    Interventions:   Drug: golimumab;   Drug: golimumab or placebo;   Drug: golimumab or placebo
    Sponsors:   Centocor, Inc.;   Schering-Plough
    Recruiting - verified November 2009

  • A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

    Conditions:   Excessive Daytime Sleepiness;   Narcolepsy
    Interventions:   Drug: Placebo;   Drug: PF-03654746
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Study of Tissue and Blood Samples From Patients With High-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: DNA ploidy analysis;   Genetic: fluorescence in situ hybridization;   Genetic: microsatellite instability analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

    Condition:   Advanced Solid Tumors
    Interventions:   Drug: CVX-241;   Drug: CVX-241;   Drug: CVX-241;   Drug: CVX-241;   Drug: CVX-241;   Drug: CVX-241
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009

  • Safety Study of PLX108-01 in Patients With Solid Tumors

    Condition:   Solid Tumors
    Intervention:   Drug: PLX3397
    Sponsor:   Plexxikon
    Recruiting - verified October 2009

  • Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

    Condition:   Ulcerative Colitis
    Interventions:   Drug: Asacol (mesalamine), High Dose;   Drug: Asacol (mesalamine), Low Dose
    Sponsor:   Procter and Gamble
    Recruiting - verified October 2009

  • Use of Misoprostol for Intrauterine Device (IUD) Insertion in Nulliparous Women

    Condition:   Contraception
    Interventions:   Drug: Misoprostol;   Drug: Placebo
    Sponsor:   University of Arizona
    Recruiting - verified October 2009

  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

    Condition:   Pregnancy Prevention
    Intervention:   Drug: DR-103
    Sponsor:   Teva Women's Health
    Recruiting - verified October 2009

  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified November 2009

  • TAXUS Libertē Post Approval Study

    Condition:   Coronary Artery Disease
    Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
    Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
    Not yet recruiting - verified November 2009

  • The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

    Condition:   Psoriasis
    Interventions:   Drug: Methotrexate and Etanercept;   Drug: Etanercept ONLY
    Sponsors:   Amgen;   Immunex Corporation
    Not yet recruiting - verified November 2009

  • Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

    Condition:   Type II Diabetes Mellitus
    Interventions:   Drug: JTT-654;   Drug: JTT-654 Placebo
    Sponsor:   Akros Pharma Inc.
    Recruiting - verified November 2009

  • Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence

    Condition:   Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
    Intervention:   Device: Coaptite®
    Sponsor:   BioForm Medical, Inc.
    Recruiting - verified November 2009

  • Safety and Tolerability of TAK-491 Plus Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Essential Hypertension

    Condition:   Essential Hypertension
    Interventions:   Drug: TAK-491 and chlorthalidone;   Drug: Olmesartan medoxomil-hydrochlorothiazide
    Sponsor:   Takeda Global Research & Development Center, Inc.
    Recruiting - verified November 2009

  • Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetic Patients That Cannot Control Their Diabetes on Metformin Alone

    Condition:   Type 2 Diabetes
    Interventions:   Drug: KRP-104;   Drug: Placebo
    Sponsors:   ActivX Biosciences, Inc.;   Kyorin Pharmaceutical Co.,Ltd
    Recruiting - verified October 2009

  • The Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis to Assess the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: Placebo;   Biological: Certolizumab pegol
    Sponsor:   UCB, Inc.
    Recruiting - verified November 2009

  • A Weight Loss Study in Overweight Men and Women

    Condition:   Obesity
    Interventions:   Drug: LY377604;   Drug: Sibutramine;   Drug: Metoprolol XL;   Drug: Placebo sibutramine;   Drug: Placebo Metoprolol XL;   Drug: Placebo LY377604
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

    Condition:   Human Papillomavirus Infection
    Interventions:   Biological: V503;   Biological: Comparator: Menactra™ (Concomitant);   Biological: Comparator: Adacel™ (concomitant);   Biological: Comparator: Menactra™ (Non-Concomitant);   Biological: Comparator: Adacel™ (Non-concomitant)
    Sponsor:   Merck
    Recruiting - verified November 2009

  • A Study of Advanced or Metastatic Non-small Cell Lung Cancer

    Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: LY2603618;   Drug: Pemetrexed
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

    Conditions:   Pain;   Back Pain;   Low Back Pain;   Back Pain With Radiation
    Interventions:   Drug: Oxycodone IR;   Drug: NUCYNTA
    Sponsors:   Ortho-McNeil Janssen Scientific Affairs, LLC;   Grünenthal
    Recruiting - verified October 2009

  • Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: BMS-790052;   Drug: Ortho Tri-Cyclen®
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified November 2009

  • Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

    Condition:   Chronic Hepatitis C Genotype-1 Relapse
    Interventions:   Drug: NIM811;   Drug: Placebo BID + SOC
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

    Conditions:   Solid Tumor;   Kidney Neoplasms;   Advanced Renal Cell Carcinoma
    Interventions:   Drug: CVX-060 + sunitinib;   Drug: CVX-060 + sunitinib;   Drug: CVX-060 + sunitinib;   Drug: CVX-060 + sunitinib;   Drug: CVX-060 + sunitinib;   Drug: Sunitinib
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

    Condition:   Influenza Infection
    Interventions:   Biological: GSK2340273A;   Biological: GSK2340274A
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • The Dual Antiplatelet Therapy Study (DAPT Study)

    Condition:   Coronary Artery Disease
    Interventions:   Drug: Placebo & Aspirin;   Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
    Sponsors:   Harvard Clinical Research Institute;   Abbott;   Boston Scientific Corporation;   Bristol-Myers Squibb;   Sanofi-Synthelabo;   Cordis Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Medtronic
    Recruiting - verified November 2009

  • A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: insulin glargine + preprandial lispro insulin;   Biological: albiglutide + insulin glargine
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Clinical Study to Test a New Drug to Treat Major Depression

    Condition:   Major Depressive Disorder (MDD)
    Interventions:   Drug: GW856653;   Other: Placebo;   Drug: GW856653
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

    Condition:   Castration-Resistant Prostate Cancer
    Interventions:   Drug: MDV3100;   Drug: Placebo
    Sponsor:   Medivation, Inc.
    Recruiting - verified November 2009

  • Efficacy and Safety Study of NBI-56418 Na in Subjects With Endometriosis

    Conditions:   Endometriosis;   Pain
    Interventions:   Drug: NBI-56418;   Drug: Placebo
    Sponsor:   Neurocrine Biosciences
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

    Conditions:   Low Back Pain;   Low Back Pain, Recurrent
    Interventions:   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: Placebo
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

    Conditions:   Osteoarthritis;   Osteoarthritis, Hip;   Osteoarthritis, Knee;   Pain;   Arthralgia;   Joint Pain
    Interventions:   Drug: JNJ-42160443;   Drug: Placebo;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials